REG - IXICO plc - Contract Win

IXICOAnnouncement

10/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241210:nRSJ3886Pa&default-theme=true

RNS Number : 3886P  IXICO plc  10 December 2024

IXICO PLC

 

("IXICO" or the "Company")

 

US Client Clinical Trial Contract Win

10 December 2024 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company")
a global leader in neuroscience imaging, using its AI-driven platform to help
advance therapy research in neurological disorders, today announces that it
has signed a contract with a new US headquartered client to provide imaging
services for a Phase 2 Huntington's Disease clinical trial. The contract
value, to be delivered over approximately 2.5 years, is worth over £0.5
million to IXICO.

 

Huntington's Disease is a rare, hereditary neurodegenerative disorder that
leads to the progressive breakdown of nerve cells in the brain, affecting
motor skills, cognitive function, mood, and emotional well-being.

 

The contract award reinforces IXICO's sustained positive commercial momentum,
as highlighted in the Company's FY24 Final Results, and aligns with its
strategic pillars of 'Innovate, Lead, Scale' to drive expansion and growth.
Throughout 2024, IXICO has also secured additional clinical trial contracts
across key therapeutic areas, including Huntington's Disease, Parkinsonian
Disorders, and Alzheimer's Disease.

 

Bram Goorden, CEO of IXICO, commented: "We are delighted to announce our
involvement in this Phase 2 clinical trial, which aims to address the urgent
need for effective treatments for Huntington's disease. This contract further
demonstrates IXICO's expertise in supporting neurodegenerative disease trials,
reinforcing our role as a trusted partner for sponsors. Through this work we
are proud to continue our support of the Huntington's Disease community, in
collaboration with our sponsor, working towards a breakthrough in this
challenging field."

 

Ends

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation 596/2014 which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018, as amended and supplemented from time to
time. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

Further information:

 

 IXICO plc                                                                         +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and                          +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks/Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUKVVRSOUURAA